SEARCH

SEARCH BY CITATION

References

  • 1
    Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn’s disease: a meta-analysis. Ann Intern Med 1995; 122: 13242.
  • 2
    Bergan S, Rugstad HE, Bentdal O, Endresen L, Stokke O. Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. Ther Drug Monit 1994; 16: 1320.
  • 3
    Dubinsky MC, Lamothe S, Yang H, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 70513.
  • 4
    Present DH, Meltzer SI, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 6419.
  • 5
    Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336: 2259.
  • 6
    Lennard L & Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989; 7: 181623.
  • 7
    Weinshilboum RM & Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase. Am J Hum Genet 1980; 32: 65162.
  • 8
    Szumlanski C, Ottemess D, Her C, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biology 1996; 15: 1730.
  • 9
    Lennard L, Van Loon LA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46: 14954.
  • 10
    Murrell GA & Rapeport WG. Clinical pharmacokinetics of allopurinol. Clin Pharmacokinet 1986; 11: 34353.
  • 11
    Lennard L. Clinical implications of thiopurine methyltransferase. Optimization of drug dosage and potential drug interactions. Ther Drug Monit 1998; 20: 52731.DOI: 10.1097/00007691-199810000-00014
  • 12
    Szumlanski CL & Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39: 4569.
  • 13
    Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug interaction. Clin Pharmacol Ther 1997; 62: 46475.
  • 14
    Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WI. Balsalazide and azathioprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology 1999; 116: 15056.
  • 15
    Bliddal H & Helin P. Leucopenia in adult Still’s disease during treatment with azathioprine and sulphasalazine. Clin Rheumatol 1987; 6: 24450.
  • 16
    Rivier G, Khamashta MA, Hughes GR. Warfarin and azathioprine: a drug interaction does exist. Am J Med 1993; 95: 342342.
  • 17
    Lennard L & Singleton H. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr Biomed Appl 1992; 583: 8390.
  • 18
    Weinshilboum RM, Raymond PA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978; 85: 32333.
  • 19
    Bystrowska B, Nowak J, Brandys J. Validation of a LC method for the determination of 5-aminosalicylic acid and its metabolite in plasma and urine. J Pharm Biomed Anal 2000; 22: 3417.
  • 20
    Gionchetti P, Campieri M, Venturi A, et al. Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation. Aliment Pharmacol Ther 1996; 10: 6015.
  • 21
    Brendel E, Meineke I, Witsch D, Zschunke M. Simultaneous determination of 5-aminosalicylic acid and 5-acetylaminosalicylic acid by high performance liquid chromatography. J Chromatogr 1987; 385: 299304.
  • 22
    Das KM, Eastwood MA, McManus JPA, Sircus W. Adverse reactions during salicylazosulphapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973; 289: 4915.
  • 23
    Das KM & Dubin R. Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet 1976; 1: 40625.